Dehydration News and Research RSS Feed - Dehydration News and Research

Dehydration is a condition caused by the loss of too much water from the body. Severe diarrhea or vomiting can cause dehydration.
Parion Sciences receives $3 million CFFT award to support development of new CF treatment

Parion Sciences receives $3 million CFFT award to support development of new CF treatment

Parion Sciences today announced it has received a $3 million award from Cystic Fibrosis Foundation Therapeutics to support the development of P-1037, Parion's new investigational treatment for cystic fibrosis (CF). [More]
Football players are found to be carriers of sickle cell trait later in life

Football players are found to be carriers of sickle cell trait later in life

From 2000 to 2014, nine collegiate football players unexpectedly collapsed and died during training. The cause? Muscle breakdown leading to organ failure. [More]
Drinking too much water and sports drinks may lead to death

Drinking too much water and sports drinks may lead to death

The recent deaths of two high school football players illustrate the dangers of drinking too much water and sports drinks, according to Loyola University Medical Center sports medicine physician Dr. James Winger. [More]
Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. [More]
Federal law enacted to combat use of "club drugs" fails to reduce drugs' popularity

Federal law enacted to combat use of "club drugs" fails to reduce drugs' popularity

A federal law enacted to combat the use of "club drugs" such as Ecstasy - and today's variation known as Molly - has failed to reduce the drugs' popularity and, instead, has further endangered users by hampering the use of measures to protect them. [More]
GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. [More]
Blood flow to the brain significantly affected by dehydration

Blood flow to the brain significantly affected by dehydration

It’s a lesson riders in the Tour de France know all too well – drinking water while cycling in extreme heat is vital if they are to remain at peak performance. [More]
Daily temperatures increase number of patients seeking treatment for kidney stones

Daily temperatures increase number of patients seeking treatment for kidney stones

As daily temperatures increase, so does the number of patients seeking treatment for kidney stones. In a study that may both reflect and foretell a warming planet's impact on human health, a research team found a link between hot days and kidney stones in 60,000 patients in several U.S. cities with varying climates. [More]
Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Researchers have found that fecal transplantation is effective and safe for treating C. difficile in immunocompromised patients. This is the result of a study led by Colleen Kelly, M.D., a gastroenterologist in the Center for Women's Gastrointestinal Medicine at The Women's Medicine Collaborative. [More]
Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Consumers worldwide spend billions of dollars each year on probiotic foods and supplements. But studies evaluating probiotics - microorganisms believed to aid digestive health - have been limited. [More]
First Edition: June 25, 2014

First Edition: June 25, 2014

Today's headlines include a report about a recent analysis that finds new health plan enrollees are showing high rates of serious health conditions. [More]
Summer offers ideal opportunity to get tonsil removal

Summer offers ideal opportunity to get tonsil removal

Pool pass, sports camp, visiting relatives and getting tonsils removed are all normal activities for children during the summer months. [More]
Review on effects of treating cholera with antimicrobial drugs

Review on effects of treating cholera with antimicrobial drugs

Researchers from the Cochrane Infectious Diseases Group, co-ordinated through the editorial base in LSTM, conducted an independent review of the effects of treating cholera with antimicrobial drugs, published in The Cochrane Library today. [More]
Researchers find shared genetic link in autoimmune response among PV patients

Researchers find shared genetic link in autoimmune response among PV patients

Autoimmune disease occurs when the body's own natural defense system rebels against itself. One example is pemphigus vulgaris (PV), a blistering skin disease in which autoantibodies attack desmoglein 3 (Dsg3), the protein that binds together skin cells. [More]
New biometric wearable devices use scattered light to monitor glucose levels and pulse

New biometric wearable devices use scattered light to monitor glucose levels and pulse

Monitoring a patient's vital signs and other physiological parameters is a standard part of medical care, but, increasingly, health and fitness-minded individuals are looking for ways to easily keep their own tabs on these measurements. Enter the biometric watch. [More]
FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval. [More]
Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine. [More]
Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell carcinoma (mBCC) taking the investigational oral compound LDE225 (sonidegib) had marked and sustained tumor shrinkage after a median follow-up of 13.9 months. [More]
Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). [More]
New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014. [More]